An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

The Maryland program’s spending on both obesity drugs grew 86% year-over-year, Real Chemistry said, the seventh highest in ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound, and other anti-obesity drugs was third-highest in the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The effects that a pause may have on your body may depend on why you're taking the medication in the first place.

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...